United Therapeutics (UTHR) Stock Forecast & Price Target

Compare

663 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

UTHR Analyst Ratings

Moderate Buy

9 Buy

4 Hold

0 Sell

Based on 13 analysts giving stock ratings to

United

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

UTHR Stock 12 Month Forecast

Average Price Target

$497.09

▲(12.10% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $497.09 with a high forecast of $580.00 and a low forecast of $328.00. The average price target represents a 12.10% change from the last price of $443.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","362":"$362","435":"$435","508":"$508","581":"$581"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":580,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$580.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":497.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$497.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$328.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,362,435,508,581],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,438.18,449.08923076923077,459.9984615384615,470.9076923076923,481.8169230769231,492.72615384615386,503.6353846153846,514.5446153846153,525.4538461538461,536.363076923077,547.2723076923077,558.1815384615385,569.0907692307692,{"y":580,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,438.18,442.71153846153845,447.2430769230769,451.7746153846154,456.30615384615385,460.8376923076923,465.36923076923074,469.90076923076924,474.4323076923077,478.96384615384613,483.4953846153846,488.0269230769231,492.55846153846153,{"y":497.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,438.18,429.7046153846154,421.22923076923075,412.75384615384615,404.27846153846156,395.8030769230769,387.3276923076923,378.8523076923077,370.37692307692305,361.90153846153845,353.42615384615385,344.9507692307692,336.4753846153846,{"y":328,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":357.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":374.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$580.00

Average Price Target$497.09

Lowest Price Target$328.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Thome

TD Cowen

$500

Buy

12.75%

Upside

Reiterated

10/02/25

United Therapeutics (UTHR) Gets a Buy from TD CowenTD Cowen analyst Joseph Thome reiterated a Buy rating and $500.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).

Ashwani Verma

UBS

$580

Buy

30.80%

Upside

Reiterated

10/01/25

UBS Reaffirms Their Buy Rating on United Therapeutics (UTHR)He noted that Courts rarely block only one indication while allowing the other under Hatch-Waxman cases.

Roger Song

Jefferies

$564

Buy

27.19%

Upside

Reiterated

10/01/25

Buy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent Litigation

Andrew Fein

H.C. Wainwright

$400→$500

Buy

12.75%

Upside

Reiterated

09/29/25

Buy Rating for United Therapeutics Amid Favorable Legal Standing in Patent LitigationValuation and Risks. Our $500 price target is based on an equally weighted composite of: (a) $459.65/ share, as a 13x multiple of taxed and diluted FY30 GAAP EPS of $54.40 discounted back to and (b) an NPV of $540.47/share, discount rate 9%, growth rate -1.0%.

Terence Flynn

Morgan Stanley

$328

Hold

-26.03%

Downside

Reiterated

09/29/25

Hold Rating for United Therapeutics' Tyvaso Amid Mixed Trial Results and Real-World Applicability Concerns

Roanna Ruiz

Leerink Partners

―

Buy

―

Reiterated

09/29/25

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), Summit Therapeutics (NASDAQ: SMMT) and United Therapeutics (NASDAQ: UTHR)

Jason Gerberry

Bank of America Securities

$463

Hold

4.41%

Upside

Reiterated

09/28/25

Hold Rating Maintained for United Therapeutics' Tyvaso Amid Competitive Landscape and Pending Data

Lisa Walter

RBC Capital

$569

Buy

28.31%

Upside

Initiated

09/26/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Olivia Brayer

Cantor Fitzgerald

$405→$525

Buy

18.39%

Upside

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)

Jessica Fye

J.P. Morgan

$345→$450

Buy

1.48%

Upside

Reiterated

09/09/25

United Therapeutics (UTHR) Receives a Buy from J.P. Morgan

Andreas Argyrides

Oppenheimer

$510→$575

Buy

29.67%

Upside

Reiterated

09/05/25

United Therapeutics price target raised to $575 from $510 at OppenheimerUnited Therapeutics price target raised to $575 from $510 at Oppenheimer

Tiago Fauth

Wells Fargo

$295→$414

Hold

-6.64%

Downside

Reiterated

09/03/25

Julian Harrison

BTIG

―

Hold

―

Reiterated

09/02/25

Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market UncertaintiesWe believe Yutrepia (LQDA [Buy $49 PT]) and TPIP (INSM [Not Rated]) are appropriately benefiting from positive readthrough today, as the topline TETON-2 results further support the long-term value of the entire inhaled treprostinil category.

Jasper Hellweg

Argus Research

$375→$345

Buy

-22.20%

Downside

Reiterated

05/06/25

United Therapeutics price target lowered to $345 from $375 at ArgusUnited Therapeutics price target lowered to $345 from $375 at Argus

Chris Shibutani

Goldman Sachs

$302→$293

Hold

-33.93%

Downside

Reiterated

02/27/25

United Therapeutics Corp. (UTHR) PT Lowered to $293 at Goldman SachsGoldman Sachs analyst Chris Shibutani lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $293.00 (from $302.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Thome

TD Cowen

$500

Buy

12.75%

Upside

Reiterated

10/02/25

United Therapeutics (UTHR) Gets a Buy from TD CowenTD Cowen analyst Joseph Thome reiterated a Buy rating and $500.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).

Ashwani Verma

UBS

$580

Buy

30.80%

Upside

Reiterated

10/01/25

UBS Reaffirms Their Buy Rating on United Therapeutics (UTHR)He noted that Courts rarely block only one indication while allowing the other under Hatch-Waxman cases.

Roger Song

Jefferies

$564

Buy

27.19%

Upside

Reiterated

10/01/25

Buy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent Litigation

Andrew Fein

H.C. Wainwright

$400→$500

Buy

12.75%

Upside

Reiterated

09/29/25

Terence Flynn

Morgan Stanley

$328

Hold

-26.03%

Downside

Reiterated

09/29/25

Hold Rating for United Therapeutics' Tyvaso Amid Mixed Trial Results and Real-World Applicability Concerns

Roanna Ruiz

Leerink Partners

―

Buy

―

Reiterated

09/29/25

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), Summit Therapeutics (NASDAQ: SMMT) and United Therapeutics (NASDAQ: UTHR)

Jason Gerberry

Bank of America Securities

$463

Hold

4.41%

Upside

Reiterated

09/28/25

Hold Rating Maintained for United Therapeutics' Tyvaso Amid Competitive Landscape and Pending Data

Lisa Walter

RBC Capital

$569

Buy

28.31%

Upside

Initiated

09/26/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Olivia Brayer

Cantor Fitzgerald

$405→$525

Buy

18.39%

Upside

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)

Jessica Fye

J.P. Morgan

$345→$450

Buy

1.48%

Upside

Reiterated

09/09/25

United Therapeutics (UTHR) Receives a Buy from J.P. Morgan

Andreas Argyrides

Oppenheimer

$510→$575

Buy

29.67%

Upside

Reiterated

09/05/25

United Therapeutics price target raised to $575 from $510 at OppenheimerUnited Therapeutics price target raised to $575 from $510 at Oppenheimer

Tiago Fauth

Wells Fargo

$295→$414

Hold

-6.64%

Downside

Reiterated

09/03/25

Julian Harrison

BTIG

―

Hold

―

Reiterated

09/02/25

Jasper Hellweg

Argus Research

$375→$345

Buy

-22.20%

Downside

Reiterated

05/06/25

United Therapeutics price target lowered to $345 from $375 at ArgusUnited Therapeutics price target lowered to $345 from $375 at Argus

Chris Shibutani

Goldman Sachs

$302→$293

Hold

-33.93%

Downside

Reiterated

02/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

1 Month

xxx

Success Rate

17/22 ratings generated profit

Average Return

+4.81%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 77.27% of your transactions generating a profit, with an average return of +4.81% per trade.

3 Months

xxx

Success Rate

13/15 ratings generated profit

Average Return

+15.21%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 86.67% of your transactions generating a profit, with an average return of +15.21% per trade.

1 Year

Roanna RuizLeerink Partners

Success Rate

13/15 ratings generated profit

Average Return

+23.85%

reiterated a buy rating 5 days ago

Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +23.85% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+41.77%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTHR Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, UTHR has received 29 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. UTHR average Analyst price target in the past 3 months is 497.09.

Each month's total comprises the sum of three months' worth of ratings.

UTHR Financial Forecast

UTHR Earnings Forecast

Next quarter’s earnings estimate for UTHR is $7.28 with a range of $6.19 to $8.88. The previous quarter’s EPS was $6.41. UTHR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year UTHR has Preformed in-line its overall industry.

UTHR Sales Forecast

Next quarter’s sales forecast for UTHR is $812.87M with a range of $778.40M to $868.50M. The previous quarter’s sales results were $798.60M. UTHR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year UTHR has Preformed in-line its overall industry.

UTHR Stock Forecast FAQ

What is UTHR’s average 12-month price target, according to analysts?

Based on analyst ratings, United Therapeutics’s 12-month average price target is 497.09.

What is UTHR’s upside potential, based on the analysts’ average price target?

United Therapeutics has 12.10% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is UTHR a Buy, Sell or Hold?

United Therapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.

What is United Therapeutics’s price target?

The average price target for United Therapeutics is 497.09. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $580.00 ,the lowest forecast is $328.00. The average price target represents 12.10% Increase from the current price of $443.44.

What do analysts say about United Therapeutics?

United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of UTHR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

United Therapeutics (UTHR) Stock Forecast & Price Target

UTHR Analyst Ratings

UTHR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering United Therapeutics

UTHR Analyst Recommendation Trends

UTHR Financial Forecast

UTHR Earnings Forecast

UTHR Sales Forecast

UTHR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts